About Suzanne Baron, MD, MSC

Dr. Baron received her BA from Harvard University, her MD from Yale School of Medicine and her MSc from Harvard School of Public Health.   She completed her internal medicine residency, cardiovascular medicine fellowship, interventional cardiology fellowship and structural heart disease fellowship at Massachusetts General Hospital.   

In addition to her clinical practice, Dr. Baron engages in research involving the effects of cardiovascular devices on healthcare costs and patient-reported outcomes and she has published on these topics in the Journal of the American College of Cardiology, JAMA Cardiology and Circulation, among many others.   She is also active within the Society for Cardiovascular Angiography and Interventions and has served as the chair for the Women in Innovations committee as well as the deputy editor for the Journal of the Society for Cardiovascular Angiography and Interventions (JSCAI).

Departments, Centers, & Programs:

Clinical Interests:

Treats:

Locations

Mass General Heart Center
55 Fruit St.
Boston, MA 02114
Phone: 617-724-7263

Medical Education

  • MD, Yale University School of Medicine
  • Residency, Massachusetts General Hospital
  • Fellowship, Massachusetts General Hospital
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Cardiovascular Disease, American Board of Internal Medicine
  • Interventional Cardiology, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Publications

  • Baron SJ, Yeh RW, Cruz-Gonzalez I, Healy JL, Pomerantsev E, Garasic J, Drachman D, Rosenfield K, Jang IK. Efficacy and safety of argatroban in patients with heparin induced thrombocytopenia undergoing endovascular intervention for peripheral arterial disease. Catheter Cardiovasc Interv 2008; 72(1): 116-20.

    Baron SJ, Arnold SV, Herrmann HC, Holmes D, Szeto WY, Allen KB, Chhatriwalla AK, Vemulapali S, O?Brien S, Dai D, Cohen DJ. Impact of ejection fraction and aortic valve gradient on outcomes of transcatheter aortic valve replacement. J Am Coll Cardiol 2016; 67 (20): 2349-58.

    Baron SJ, Lei Y, Chinnakondepalli J, Vilain K, Magnuson EA, Kereiakes DJ, Ellis SG, Stone GW, Cohen DJ on behalf of the ABSORB III Investigators. Economic outcomes of bioresorbable vascular scaffolds vs. everolimus-eluting stents in patients undergoing percutaneous coronary intervention: One year results from the ABSORB III trial. JACC Cardiovasc Interv 2017; 10(8): 774-82.

    Baron SJ, Arnold SV, Wang K, Magnuson EA, Chinnakondepali K, Makkar R, Herrmann HC, Kodali S, Thourani VH, Kapadia S, Svensson L, Brown DL, Mack MH, Smith CR, Leon MB, Cohen DJ. Health status benefits of transcatheter vs. surgical aortic valve replacement in patients with severe aortic stenosis at intermediate surgical risk: results from the PARTNER 2 randomized clinical trial. JAMA Cardiol 2017; 2(8): 837-45.

    Baron SJ, Chinnakondepalli K, Magnuson EA, Kandzari DE, Puskas JD, Ben-Yehuda O, Es G-Av, Taggart DP, Morice M-C, Lembo NJ, Brown III WM, Banning A, Simonton CA, Kappetein AP, Sabik JF, Serruys PW, Stone GW, Cohen DJ, on behalf of the EXCEL Investigators. Quality of Life after Everolimus-Eluting Stents or Bypass Surgery for Treatment of Left Main Disease. J Am Coll Cardiol 2017; 70(25): 3113-3122.

    Baron SJ, Arnold SV, Reynolds MR, Wang K, Deeb M, Reardon MR, Hermiller J, Yakubov SJ, Adams SH, Popma JJ, Cohen DJ on behalf of the US CoreValve Investigators. Durability of quality of life benefits of transcatheter aortic valve replacement: Long-term results from the CoreValve US Extreme Risk Trial. Am Heart J 2017; 194: 39-48.

    Baron SJ, Thourani VH, Kodali S, Arnold SV, Wang K, Magnuson EA, Pichard AD, Babaliaros V, George I, Miller DC, Tuzcu EM, Greason K, Herrmann HC, Smith CR, Leon MB, Cohen DJ on behalf of the PARTNER 2 Investigators. Effect of SAPIEN 3 transcatheter valve implantation on health status in patients with severe aortic stenosis at intermediate surgical risk: Results from the PARTNER S3i Trial. JACC Cardiovasc Interv 2018; 11: 1188-98.

    Baron SJ, Wang K, House JA, Magnuson EA, Reynolds MR, Makkar R, Herrmann HC, Kodali S, Thourani VH, Kapadia S, Svensson L, Mack MH, Brown DL, Russo MJ, Smith CR, Webb J, Miller C, Leon MB, Cohen DJ on behalf of the PARTNER 2 Investigators. Cost-effectiveness of transcatheter vs. surgical aortic valve replacement in patients with severe aortic stenosis at intermediate risk: Results from the PARTNER 2 trial. Circulation 2019; 139: 877-88.

    Baron SJ, Magnuson EA, Lu M, Wang K, Chinnakondepalli K, Mack M, Thourani VH, Kodali S ,Makkar R, Herrmann HC, Kapadia S, Babaliaros V, Williams MR, Kereiakes D, Zajarias A, Alu MC, Webb JG, Smith CR, Leon MB, Cohen DJ for the PARTNER 3 Investigators. Health status after transcatheter vs. surgical aortic valve replacement in low-risk patients with aortic stenosis. J Am Coll Cardiol 2019; 74 (23): 2833-2842.

    Baron SJ, Wang K, Arnold SV, Magnuson EA, Whisenant B, Brieke A, Rinaldi M, Asgar AW, Lindenfeld, J, Abraham WT, Mack MJ, Stone GW, Cohen DJ for the COAPT Investigators. Cost-effectiveness of transcatheter mitral valve repair versus medical therapy in patients with heart failure and secondary mitral regurgitation: Results from the COAPT trial. Circulation 2019; 140 (23): 1881-91.

    Baron SJ, Ryan MP, Moore KA, Clancy SJ, Gunnarsson CL. Contemporary costs associated with transcatheter versus surgical aortic valve replacement in medicare beneficiaries. Circ Cardiovasc Interv 2022; 15(3): e011295. Doi: 10.1161/CIRCINTERVENTIONS.121.011295. Epub 2022 Feb 23.

Reviews: Comments and Ratings